Actavis to acquire Allergan for $66B

Allergan, a Botox maker, accepted a $66 billion takeover bid from Actavis, according to a Reuters report.

Advertisement

Actavis offered $219 per share in cash and stock, and its shares rose 1.7 percent to $247.94. The deal, however, also included $400 million in research and development cuts for Allergan. The new company will operate from both California, where Allergan is based, and New Jersey, where Actavis is headquartered.

Actavis is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and innovative branded pharmaceutical products.

Valeant Pharmaceuticals International was also in the running acquire Allergan, however the company settled for Actavis’ offer, according to the report.

More articles on gastroenterology:

Cantel Medical names Jorgen Hansen president, COO
Hanover Gastroenterology expands
GI physician to know: Dr. David Rubin of University of Chicago Medicine

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

  • Premier Health Partners has acquired Dayton, Ohio-based Digestive Specialists, according to a notice posted on the website of law firm…

Advertisement

Comments are closed.